

Editorial Questionnaire

Your comments are important to us. This form provides you with the opportunity to express your opinions. Our goal is to make *CNS Spectrums* your source for practical and clinical neuropsychiatric information. By filling out this Questionnaire, you enable us to incorporate your views about our editorial content in future issues. Please fill out this form in its entirety. Thank you.

Name (please print)

Address

City

State

Zip Code

E-mail

Specialty

Signature

Date

**Fax this form to 212-328-0600. Or mail it to: CNS SPECTRUMS, MBL Communications, Inc.,
333 Hudson Street, 7th Floor, New York, NY 10013**

1. On a scale of 1 to 5 (1=Poor, 5=Excellent), please indicate your level of interest and/or satisfaction with the editorial content in this issue.

3. Please describe your reading pattern for this issue:

- Read cover to cover
- Skimmed table of contents
- Read select items of interest
- Skimmed text
- Did not read

Original Research and Review Articles

Migraines: Neurological and Psychiatric Perspectives

1 2 3 4 5

4. On a scale of 1 to 5 (1=Incomplete, 5=Comprehensive), how would you describe the depth of coverage for this issue?

1 2 3 4 5

Departments

Clinical Updates in Neurology

1 2 3 4 5

Clinical Updates in Psychiatry

1 2 3 4 5

CME

1 2 3 4 5

Case Reports

1 2 3 4 5

The Neurology of Behavior

1 2 3 4 5

5. Any other comments about *CNS Spectrums'* editorial content, design, or overall usefulness?

2. Which areas of neuropsychiatry would you like us to cover in the future?

6. Please indicate your title:

- Psychiatrist
- Neurologist

Please select any of the following educational materials you would like to receive:

CME Accredited CNS Roundtable Monographs and CD-ROMs

- Pharmacologic Advances in the Treatment of ADHD
- The Use of Lithium in Bipolar Disorder
- Atypical Antipsychotics in the Treatment of Bipolar Disorder
- Recognizing Comorbidities Associated With ADHD
- Remission-Oriented Treatment Considerations of Bipolar Disorder

Clinical Pocket Reference Guides

- The 2003 Black Book of Psychotropic Dosing and Monitoring
- The Diagnostic and Therapeutic Guide to Sleep Disorders
- The Effects of Antidepressants on Human Sexuality
- Dosing and Monitoring Guidelines: Mood Disorders
- The Side-Effect Profiles of Antipsychotic Medications

First-line treatment for schizophrenia

Well!

Proven to
reduce positive and
negative symptoms¹⁻⁴

Accepted!

Favorable EPS*, prolactin,
and weight profiles^{1,2,5-7}

Treatment you can count on!

- The fastest-growing product among the top 3 prescribed atypical antipsychotics⁸
- Over 5 years of clinical experience and 14.2 million prescriptions⁹

The most common adverse events associated with the use of SEROQUEL are dizziness (10%), postural hypotension (7%), dry mouth (7%), and dyspepsia (6%). The majority of adverse events are mild or moderate. In 3- to 6-week, placebo-controlled trials, the incidence of somnolence was 18% with SEROQUEL vs 11% with placebo.

As with all antipsychotic medications, prescribing should be consistent with the need to minimize the risk of tardive dyskinesia, seizures, and orthostatic hypotension.

As with all antipsychotic medications, a rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported.

*Extrapyramidal symptoms.

References: 1. Small JG, Hirsch SR, Arvanitis LA, et al, and the SEROQUEL Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. *Arch Gen Psychiatry*. 1997;54:549-557. 2. Arvanitis LA, Miller BG, and the SEROQUEL Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. *Biol Psychiatry*. 1997;42:233-246. 3. Borison RL, Arvanitis LA, Miller BG and the U.S. SEROQUEL Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. *J Clin Psychopharmacol*. 1996;16:158-169. 4. Data on file, Study S91, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. 5. SEROQUEL[®] (quetiapine fumarate) Prescribing Information, Rev 1/01, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. 6. Brecher M, Rak IW, Melvin K, et al. The long-term effect of quetiapine (Seroquel[™]) monotherapy on weight in patients with schizophrenia. *Int J Psych Clin Pract*. 2000;4:287-291. 7. Data on file. DA-SER-02, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. 8. NPA Plus[™] data for dispensed TRxs for the top 3 atypicals (2002 vs 2001), Atypical Market, IMS America, Ltd., 2002. 9. Data on file, DA-SER-10, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.

 **Seroquel**[®]
quetiapine fumarate
25 mg, 100 mg, 200 mg & 300 mg tablets

Treatment patients can **LIVE** with!

AstraZeneca 

AstraZeneca Pharmaceuticals LP
210732 3/03

© 2003 AstraZeneca Pharmaceuticals LP. All rights reserved. SEROQUEL is a registered trademark of the AstraZeneca group of companies.
Please see Brief Summary of Prescribing Information on following page. www.SEROQUEL.com